BRAF and melanoma: The triarylimidazole 1j with a phenylpiperazine ring D is the most promising compound, with nanomolar activity in the mutant BRAF inhibition assay, the cellular pERK inhibition and the mutant BRAF melanoma WM266.4 growth inhibition.